The Pipeline

Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. We have three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO).

Our second product candidate is MVT-602, an oligopeptide kisspeptin-1 receptor agonist. We are developing MVT-602 for the treatment of female infertility as part of assisted reproduction.

Compound Indication Preclinical Phase 1 Phase 2 Phase 3
Uterine Fibroids - Heavy Menstrual Bleeding Phase 2 Complete
Endometriosis - Pain Phase 2 Complete
Advanced Prostate Cancer Phase 2 Complete
Female Infertility as Part of Assisted Reproduction Entering Phase 1
Relugolix - Japanese Development (Takeda)
Uterine Fibroids - Heavy Menstrual Bleeding Phase 3 Complete
Uterine Fibroids - Pain Phase 3 Complete

Clinical TRIALS

To learn more about Myovant’s clinical trials, please visit To learn more about those trials that are still enrolling, please visit (for pain associated with endometriosis).